Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin-EIR in Papulopustular Rosacea
NCT03864978Phase 2Unknown
- Sponsor
- Alfasigma
- Start
- Jun 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in papulopustular rosacea, sponsored by Alfasigma. Status: unknown.
02
Drugs
rifaximin
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT03864978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864978.